In brief: EU approval for Otsuka & Lundbeck’s schizophrenia treatment

FDA accepts NDA for investigational antibiotic
Credit: Shutterstock.com/ Piotr Adamowicz

The European Commission has granted approval to Otsuka Pharmaceutical and Lundbeck for Rzulti for treating adults with schizophrenia.

The companies will now work with local pricing and reimbursement bodies in countries throughout Europe to help ensure that eligible patients are able to access Rxulti.

The medicine is expected to be made available in the first EU markets during first half of 2019.